Theravance Biopharma, Inc. (TBPH)
PHARMACEUTICAL PREPARATIONS
Theravance Biopharma, Inc. (TBPH) was listed on Nasdaq from May 16, 2014 and stopped trading under the symbol TBPH on September 24, 2026.
- Listed On
- Nasdaq
- Listed Since
- May 16, 2014
- Stopped Trading
- September 24, 2026
- Employees
- 90
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 174 institutions reported holding TBPH, with 48.1 million shares worth $817.3 million in aggregate. The largest reported holder was Madison Avenue Partners, with 9.2 million shares worth $156.6 million. Of the 5 largest holders listed below, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Madison Avenue Partners | 9,212,252 | $157M | Reduced 3.14% |
| Weiss Asset Management | 7,457,060 | $127M | Unchanged |
| BlackRock | 4,562,487 | $78M | Added 6.2% |
| Newtyn Management | 3,434,191 | $58M | Reduced 29.07% |
| Irenic Capital Management | 2,760,948 | $47M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TBPH?
Theravance Biopharma, Inc. (TBPH) was listed on Nasdaq from May 16, 2014 and stopped trading under the symbol TBPH on September 24, 2026.
Who are the largest institutional holders of TBPH?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TBPH were Madison Avenue Partners, Weiss Asset Management and BlackRock.
How many institutions own TBPH?
174 institutions reported a position in TBPH for the quarter ended June 30, 2026, worth $817.3 million in total.
Did institutions buy or sell TBPH last quarter?
Of the 5 largest reported holders, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for TBPH.
Every reported institutional holder, plus insider and congressional trades in TBPH, on SentiSense.